ERBB2 and breast cancer: In a study on the effect of delayed adjuvant therapy on the prognosis of patients with breast cancer after surgery, Gagliato [35] indicated that patients with HER2-positive breast cancer who started adjuvant therapy with trastuzumab at ≥61 days after surgery had a significantly increased risk of mortality of more than 3 times compared with patients who started adjuvant therapy at ≤30 days after surgery.